Document is current
Any future updates will be listed below
-
Authors
El-Shennawy, Lamiaa
Hoffmann, Andrew D.
Dashzeveg, Nurmaa Khund
McAndrews, Kathleen M. https://orcid.org/0000-0002-4092-4991
Mehl, Paul J.
Cornish, Daphne https://orcid.org/0000-0003-3835-5694
Yu, Zihao
Tokars, Valerie L.
Nicolaescu, Vlad
Tomatsidou, Anastasia
Mao, Chengsheng https://orcid.org/0000-0002-1515-9626
Felicelli, Christopher J.
Tsai, Chia-Feng
Ostiguin, Carolina
Jia, Yuzhi
Li, Lin
Furlong, Kevin
Wysocki, Jan
Luo, Xin
Ruivo, Carolina F.
Batlle, Daniel
Hope, Thomas J. https://orcid.org/0000-0001-7183-8319
Shen, Yang https://orcid.org/0000-0002-1703-7796
Chae, Young Kwang
Zhang, Hui
LeBleu, Valerie S.
Shi, Tujin
Swaminathan, Suchitra
Luo, Yuan https://orcid.org/0000-0003-0195-7456
Missiakas, Dominique https://orcid.org/0000-0001-6482-9633
Randall, Glenn C.
Demonbreun, Alexis R.
Ison, Michael G. https://orcid.org/0000-0003-3347-9671
Kalluri, Raghu https://orcid.org/0000-0002-2190-547X
Fang, Deyu https://orcid.org/0000-0002-4211-2751
Liu, Huiping https://orcid.org/0000-0003-4822-7995
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1F32CA257345-01)
Chicago Biomedical Consortium A-017
- License Information
-
More Information
Article History
Received: 19 September 2021
Accepted: 23 December 2021
First Online: 20 January 2022
Competing interests
: MD Anderson Cancer Center and R.K. hold patents in the area of exosome biology (unrelated to the topic of this publication) and are licensed to Codiak Biosciences Inc. MD Anderson Cancer Center and R.K. are stock equity holders in Codiak Biosciences Inc. R.K. is a consultant and a scientific advisor of Codiak Biosciences Inc. Northwestern University and H.L., D.F., L.E., A.D.H., and N.K.D. hold issued and/or provisional (on evACE2) patents in the area of exosome therapeutics. H.L., D.F., and A.D.H. are scientific co-founders in ExoMira Medicine Inc. D.B. and J.W. are co-inventors of patents entitled “Active Low Molecular Weight Variants of Angiotensin-Converting Enzyme 2 (ACE2)”, “Active low molecular weight variants of Angiotensin-Converting Enzyme 2 (ACE2) for the treatment of diseases and conditions of the eye” and “Soluble ACE2 Variants and Uses Therefor.” D.B. is the founder of Angiotensin Therapeutics Inc. D.B. has received consulting fees from AstraZeneca, Relypsa, and Tricida, all unrelated to this work. J.W. reports scientific advisor capacity for Angiotensin Therapeutics Inc.
